Effect of Simethicone to length of stay in gynecologic patient, Thai

Effect of Simethicone to length of stay in benign gynecologic surgery, randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210204012

Enrollment

182

Registered

2021-02-04

Start date

2021-02-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age 18 years or more elective laparotomy in benign gynecologic surgery simethicone length of stay benign gynecologic surgery ERAS

Interventions

Simeticone 80 mg 2 tablets for chewing immediately after surgery,other group receive no drug immediately after surgery

Experimental Drug,No Intervention Drug

simethicone 160 mg,non-simethicone

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: elective laparotomy for benign gynecologic surgery willing to enroll

Exclusion criteria

Exclusion criteria: simethicone allergy emergency surgery unwilling to enrolled

Design outcomes

Primary

Measure	Time frame
length of stay 3days days	—

Secondary

Measure	Time frame
Factors associated length of stay 3days Blood loss,side effector Simeticone 3days GI symptoms,patient satisfaction 3days ask patients rate of satisfaction from 1 to 10	—

Countries

Thailand

Contacts

Public ContactKanchanok Taemamu

Faculty of medicine Siriraj hospital

t.kanchanok3@gmail.com0869081114

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026